Soleno Therapeutics Inc. (NASDAQ:SLNO) is a cheap US stock to buy, with Wolfe Research analyst Kalpit Patel initiating coverage with an Outperform rating and $75 price target. Concerns over patient slowdown are dismissed, as Soleno’s Q3 2025 earnings report shows positive net income of $26 million from increased sales of ViCAT XR, with total revenue reaching $66 million. The company has broad coverage and 764 active patients on the drug.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases. Despite its potential as an investment, there are AI stocks with greater upside potential and less downside risk, according to analysts. An undervalued AI stock that could benefit from Trump-era tariffs and onshoring trend is recommended for investors seeking growth opportunities.

For more investment insights, check out the list of 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns